WO2004056374A8 - Use of glycyrrhizin for the treatment of standard therapy-resistant hepatitis c patients - Google Patents
Use of glycyrrhizin for the treatment of standard therapy-resistant hepatitis c patientsInfo
- Publication number
- WO2004056374A8 WO2004056374A8 PCT/EP2003/014825 EP0314825W WO2004056374A8 WO 2004056374 A8 WO2004056374 A8 WO 2004056374A8 EP 0314825 W EP0314825 W EP 0314825W WO 2004056374 A8 WO2004056374 A8 WO 2004056374A8
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- glycyrrhizin
- treatment
- patients
- standard therapy
- resistant hepatitis
- Prior art date
Links
- 239000004378 Glycyrrhizin Substances 0.000 title abstract 2
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 title abstract 2
- 229960004949 glycyrrhizic acid Drugs 0.000 title abstract 2
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 title abstract 2
- 235000019410 glycyrrhizin Nutrition 0.000 title abstract 2
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 title abstract 2
- 238000011301 standard therapy Methods 0.000 title abstract 2
- 208000006454 hepatitis Diseases 0.000 title 1
- 231100000283 hepatitis Toxicity 0.000 title 1
- 208000010710 hepatitis C virus infection Diseases 0.000 abstract 1
- 239000002207 metabolite Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Saccharide Compounds (AREA)
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2003300550A AU2003300550A1 (en) | 2002-12-23 | 2003-12-23 | Use of glycyrrhizin for the treatment of standard therapy-resistant hepatitis c patients |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP02028803.1 | 2002-12-23 | ||
EP02028803 | 2002-12-23 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2004056374A1 WO2004056374A1 (en) | 2004-07-08 |
WO2004056374A8 true WO2004056374A8 (en) | 2004-12-16 |
Family
ID=32668742
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2003/014825 WO2004056374A1 (en) | 2002-12-23 | 2003-12-23 | Use of glycyrrhizin for the treatment of standard therapy-resistant hepatitis c patients |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU2003300550A1 (en) |
WO (1) | WO2004056374A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5710482B2 (en) | 2008-09-11 | 2015-04-30 | アンスティテュ・パストゥール | Monitoring and inhibition of human immunodeficiency virus infection by modulation of HMGB1-dependent induced HIV-1 replication and persistence |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2717964B2 (en) * | 1987-10-16 | 1998-02-25 | 丸善製薬株式会社 | Method for producing glycyrrhizin |
JPH03255037A (en) * | 1990-03-02 | 1991-11-13 | Santen Pharmaceut Co Ltd | Glycyrrhizin pharmaceutical preparation |
-
2003
- 2003-12-23 AU AU2003300550A patent/AU2003300550A1/en not_active Abandoned
- 2003-12-23 WO PCT/EP2003/014825 patent/WO2004056374A1/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
WO2004056374A1 (en) | 2004-07-08 |
AU2003300550A1 (en) | 2004-07-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL165860A0 (en) | Administration of therapeutic viruses | |
WO2003072035A8 (en) | Compositions and methods for the treatment of immune related diseases | |
WO2004041170A9 (en) | Compositions and methods for the treatment of immune related diseases | |
EP1492563A4 (en) | Compositions and methods for the diagnosis and treatment of herpes simplex virus infection | |
EP1572095A4 (en) | S-l-2 -deoxynucleosides for the treatment of resistant hbv strains and combination therapies | |
WO2004024097A9 (en) | Compositions and methods for the treatment of immune related diseases | |
PL376454A1 (en) | 1-acyl-pyrrolidine derivatives for the treatment of viral infections | |
AU2003231866A1 (en) | Herbs and herbal combinations useful for the treatment of microbial infections | |
AUPR839001A0 (en) | Dosage form, device and methods of treatment | |
ZA200303037B (en) | Herbal pharmaceutical composition for treatment of HIV/Aids patients. | |
AU2002347152A1 (en) | Immune globulin formulations for the treatment and prevention of an orthopoxvirus infection | |
AU2002219881A1 (en) | Methods and compositions for the treatment of human immunodeficiency virus infection | |
EP1765330A4 (en) | Pyranoindole derivatives and the use thereof for the treatment of hepatitis c virus infection or disease | |
AU2003210659A1 (en) | Combination therapy for treatment of hiv infection | |
AU2002322082A1 (en) | Pharmaceutical composition for the treatment of viral infection | |
TWI347845B (en) | Pharmaceutical compositions,combinations,and kits for the treatment of respiratory diseases and use of the same | |
AU2002325169A1 (en) | Pharmaceutical composition for the prophylaxis and/or treatment of virus diseases | |
AU2003249930A1 (en) | Proteaseome inhibitors for the treatment of herpesviridae infected individuals | |
WO2004056374A8 (en) | Use of glycyrrhizin for the treatment of standard therapy-resistant hepatitis c patients | |
AU2003237088A1 (en) | Compounds, compositions and methods for treating or preventing viral infections and associated diseases | |
AU2002327531A1 (en) | Therapeutic compositions and methods for treating viral infection | |
AU2002332613A1 (en) | Compositions and therapeutic methods for viral infection | |
AU2002323443A1 (en) | Compositions and methods for the diagnosis and treatment of herpes simplex virus infection | |
AU2003287216A1 (en) | Gb virus c and methods of treating viral infections | |
AU2002249891A1 (en) | Compounds and methods for the diagnosis and treatment of babesia infection |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
CFP | Corrected version of a pamphlet front page | ||
CR1 | Correction of entry in section i |
Free format text: IN PCT GAZETTE 28/2004 UNDER (71) REPLACE "(FOR US ONLY)" BY "(FOR ALL DESIGNATED STATES EXCEPT US)" |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase in: |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |